| The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects W Tang, Z Chen, W Zhang, Y Cheng, B Zhang, F Wu, Q Wang, S Wang, ... Signal transduction and targeted therapy 5 (1), 87, 2020 | 584 | 2020 |
| norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis P Fickert, GM Hirschfield, G Denk, HU Marschall, I Altorjay, M Färkkilä, ... Journal of hepatology 67 (3), 549-558, 2017 | 275 | 2017 |
| Methanobactin reverses acute liver failure in a rat model of Wilson disease J Lichtmannegger, C Leitzinger, R Wimmer, S Schmitt, S Schulz, Y Kabiri, ... The Journal of clinical investigation 126 (7), 2721-2735, 2016 | 151 | 2016 |
| Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: a retrospective multicenter analysis T Hildebrand, N Pannicke, A Dechene, DN Gotthardt, G Kirchner, ... Liver Transplantation 22 (1), 42-52, 2016 | 136 | 2016 |
| 1, 25-(OH) 2-vitamin D3 prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4−/− model FP Reiter, S Hohenester, JM Nagel, R Wimmer, R Artmann, L Wottke, ... Biochemical and biophysical research communications 459 (2), 227-233, 2015 | 56 | 2015 |
| The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma L Ye, J Mayerle, A Ziesch, FP Reiter, AL Gerbes, EN De Toni Cell death discovery 5 (1), 86, 2019 | 52 | 2019 |
| Liver transplantation for acute intermittent porphyria M Lissing, G Nowak, R Adam, V Karam, A Boyd, L Gouya, W Meersseman, ... Liver transplantation 27 (4), 491-501, 2021 | 49 | 2021 |
| Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4-/-mouse model FP Reiter, R Wimmer, L Wottke, R Artmann, JM Nagel, MO Carranza, ... World journal of hepatology 8 (8), 401, 2016 | 44 | 2016 |
| Tauro-β-muricholic acid restricts bile acid-induced hepatocellular apoptosis by preserving the mitochondrial membrane potential GU Denk, CP Kleiss, R Wimmer, T Vennegeerts, FP Reiter, S Schulz, ... Biochemical and biophysical research communications 424 (4), 758-764, 2012 | 38 | 2012 |
| Modulation of liver inflammation and fibrosis by interleukin-37 S Mountford, M Effenberger, H Noll-Puchta, L Griessmair, A Ringleb, ... Frontiers in immunology 12, 603649, 2021 | 36 | 2021 |
| Soluble intracellular adhesion molecule, M 30 and M 65 as serum markers of disease activity and prognosis in cholestatic liver diseases G Denk, AJ Omary, FP Reiter, S Hohenester, R Wimmer, S Holdenrieder, ... Hepatology Research 44 (13), 1286-1298, 2014 | 31 | 2014 |
| Treating hepatitis D with bulevirtide–Real-world experience from 114 patients C Dietz-Fricke, F Tacke, C Zöllner, M Demir, HH Schmidt, C Schramm, ... Jhep Reports 5 (4), 100686, 2023 | 29 | 2023 |
| Antifibrotic effects of hypocalcemic vitamin D analogs in murine and human hepatic stellate cells and in the CCl4 mouse model FP Reiter, L Ye, F Bösch, R Wimmer, R Artmann, A Ziesch, V Kanitz, ... Laboratory investigation 99 (12), 1906-1917, 2019 | 24 | 2019 |
| Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol NB Khaled, M Seidensticker, J Ricke, J Mayerle, B Oehrle, D Rössler, ... Future Oncology 18 (12), 1423-1435, 2022 | 20 | 2022 |
| Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells FP Reiter, G Denk, A Ziesch, A Ofner, R Wimmer, S Hohenester, ... Cellular Oncology 42, 705-715, 2019 | 20 | 2019 |
| IL-18 but not IL-1 signaling is pivotal for the initiation of liver injury in murine non-alcoholic fatty liver disease S Hohenester, V Kanitz, T Schiergens, C Einer, J Nagel, R Wimmer, ... International journal of molecular sciences 21 (22), 8602, 2020 | 18 | 2020 |
| Prevalence, resistance rates, and risk factors of pathogens in routine bile cultures obtained during endoscopic retrograde cholangiography FP Reiter, W Obermeier, J Jung, G Denk, UM Mahajan, EN De Toni, ... Digestive Diseases 39 (1), 42-51, 2021 | 17 | 2021 |
| Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study D Roessler, O Öcal, AB Philipp, D Markwardt, S Munker, J Mayerle, ... Journal of Cancer Research and Clinical Oncology 149 (7), 3065-3073, 2023 | 14 | 2023 |
| Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors F Bösch, AV Bazhin, S Heublein, K Brüwer, T Knösel, FP Reiter, ... BMC cancer 19, 1-8, 2019 | 14 | 2019 |
| Extending the use of atezolizumab and bevacizumab to a liver transplant recipient: need for a posttransplant registry NB Khaled, D Roessler, FP Reiter, M Seidensticker, M Guba, EN De Toni Liver Transplantation 27 (6), 928-929, 2021 | 13 | 2021 |
